HSIC vs MCK
Henry Schein and McKesson Corporation, both Healthcare
McKesson Corporation is the larger company at $111B against $9.4B. On trailing earnings HSIC is the cheaper of the two at a P/E of 24.6 against 25.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year MCK returned +37% against +24% for HSIC. The RyuScore puts MCK ahead, 86 against 61 out of 100.
| Figure | HSIC | MCK |
|---|---|---|
| Last close | $84.26 | $955 |
| Market cap | $9.4B | $111B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.6 | 25.6 |
| 1-year return | +24% | +37% |
| 5-year return | +7.4% | +380% |
| RyuScoresector-relative, 1–10 | 61/100 | 86/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Henry Schein
Revenue of $3.5B in Q2 2026, net income $94M. Its largest reported line is Global Distribution And Value Added Services, 69% of the disclosed total.
McKesson Corporation
Revenue of $105B in Q1 2027, net income $614M. Its largest reported line is North American Pharmaceutical, 82% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.